MAIN APPROACHES TO DYSLIPIDEMIA TREATMENT ACCORDING TO INTERNATIONAL GUIDELINES 2015–2016 YEARS
https://doi.org/10.21886/2219-8075-2017-1-4-11
Abstract
This article is devoted to contemporary approaches on statins and non-statin lipid-lowering drugs using according to authoritative Recommendations 2015-2016. Both approaches for cardiovascular risk levels estimation with life-style changes intervention, target level of lipid profile’s parameters and characteristics of statins and non-statin hypolipidemic drugs using for dyslipidemia control in different patient’s categories including children, women, oldest, patients with diabetes mellitus, chronic kidney disease, acute coronary syndrome and post- invasive intracoronary procedures, atherosclerosis-associated peripheral arteries disease are presented. The system literature search is performed on Scopus databases, Web of Science, MedLine, elibrary,
RISC and other.
About the Authors
A. E. Bagriy
Donetsk national medical university n. a. M. Gorkiy
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
M. V. Khomenko
Donetsk national medical university n. a. M. Gorkiy
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
I. N. Tsiba
Donetsk national medical university n. a. M. Gorkiy
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
V. A. Еfremenko
Donetsk national medical university n. a. M. Gorkiy
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
E. V. Schukina
Donetsk national medical university n. a. M. Gorkiy
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
O. A. Prikolotа
Donetsk national medical university n. a. M. Gorkiy
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
A. I. Vlasenko
Donetsk national medical university n. a. M. Gorkiy
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
Ukraine
16 Illicha st., Donetsk 83003, Ukraine
References
1.
2. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37(39):2999-3058. doi: 10.1093/eurheartj/ehw272
3. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2016; 37(29):2315-2381. doi: 10.1093/eurheartj/ehw106
4. Drozda JP, Ferguson TB, Jneid H, Krumholz HM, Nallamothu BK, Olin JW, Ting HH. 2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures. Journal of The American College Cardiology. 2016;67(5):558-587. doi: 10.1016/j.jacc.2015.02.003
5. Kukharchuk VV, Konovalov GA, Susekov AV, Sergienko IV, Semenova AE, Gornyakova NB et al. Diagnostika i korrektsiya narushenii lipidnogo obmena s tsel’yu profilaktiki i lecheniya ateroskleroza. Rossiiskie rekomendatsii (V peresmotr). Moscow; 2012. (In Russ) Available from: http://www.scardio.ru/content/Guidelines/rek_lipid_2012.pdf. Accessed on October, 31, 2016
6. Stone NJ, Lloyd-Jones DM. Lowering LDL. Cholesterol Is Good, but How and in Whom? The New England Journal of Medicine. 2015;372:1564-1565. doi: 10.1056/NEJMe1502192
7. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G et al. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of Clinical Lipidology. 2015;9(6):S1–S122. doi: 10.1016/j.jacl.2015.09.002
8. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. The New England Journal of Medicine. 2015;372(25):2387-2397. doi: 10.1056/NEJMoa1410489
9. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y et al. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome The IMPROVE-IT Trial. Journal of the American College Cardiology. 2016;67(4):353–361. doi: 10.1016/j.jacc.2015.10.077
10. Bakris G, Blonde L, Andrew M, Boulton JM, D’Alessio D, de Groot M et al. American Diabetes Association (ADA) Standards of Medical Care in Diabetes 2016 Cardiovascular disease and risk management. Diabetes Care. 2016;39:S60-S71. doi: 10.2337/dc16-S011
11. Antman EM. Clinical practice guidelines for chronic cardiovascular disorders: roadmap for the future. Journal of the American Medical Association. 2014;311(12):1195-1196. doi: 10.1001/jama.2014.1742
12. Susekov AV. Lipid-Lowering Therapy: a Look Into the Past and Prospects For the Near Future. Kardiologiya. 2016;56(6):81-88. (In Russ) doi: 10.18565/cardio.2016.6.81-88
13. Ivashkin VT., Drapkina OM. Rekomendatsii po diagnostike i lecheniyu nealkogol’noi zhirovoi bolezni pecheni. Moscow; 2012. (in Russ). Available from: http://www.gastro-j.ru/article/718-h2-klinicheskie-rekomendatsii-nbsp-po-diagnostike-i-lecheniyunealkogolnoy-zhirovoy-bolezni-pech/ Accessed on October, 31, 2016
14. Astrakova KS, Ragino YuI, Shakhtshneider EV, Voevoda MI. Proprotein Convertase Subtilisin/Kexin-Type 9 (PCSK9) – New Opportunities of Lipid-Lowering Therapy. Kardiologiya. 2016;9:84–91. (In Russ) doi: 10.18565/cardio.2016.9.84-91
Review
For citations:
Bagriy A.E., Khomenko M.V., Tsiba I.N., Еfremenko V.A., Schukina E.V., Prikolotа O.A., Vlasenko A.I. MAIN APPROACHES TO DYSLIPIDEMIA TREATMENT ACCORDING TO INTERNATIONAL GUIDELINES 2015–2016 YEARS. Medical Herald of the South of Russia. 2017;(1):4-11. (In Russ.) https://doi.org/10.21886/2219-8075-2017-1-4-11
Views:
1679
Email this article 